This clinical trial is focused on understanding how the brain responds to different forms of ketamine, a medication often used for its antidepressant effects. The study involves healthy volunteers who do not have any medical conditions. The main goal is to explore how ketamine affects brain activity and metabolism, which refers to the chemical processes that occur within the brain. The study will use advanced imaging techniques, such as PET (Positron Emission Tomography) and MR (Magnetic Resonance) imaging, to observe these effects.
Participants in the study will receive either ketamine hydrochloride or esketamine hydrochloride, both of which are forms of ketamine, or a saline solution, which is a simple saltwater solution. These substances will be administered through an intravenous injection, meaning they will be given directly into a vein. The study aims to gather information on how these substances influence brain functions, such as blood flow and connectivity between different brain regions.
The trial will also collect behavioral data to understand how the application of ketamine affects participants’ behavior. This research is important for optimizing the procedures used in the study and demonstrating the feasibility of using this novel imaging approach. The study is expected to continue until the end of 2025, with recruitment starting in December 2024.



Austria